vs
Direct Digital Holdings, Inc.（DRCT）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Direct Digital Holdings, Inc.的1.1倍（$9.1M vs $8.4M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -138.7%，领先78.3%），Direct Digital Holdings, Inc.同比增速更快（-7.4% vs -49.9%），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -38.6%）
Devolver Digital是一家总部位于美国得克萨斯州奥斯汀的电子游戏发行商，专注于独立游戏发行业务。公司由奈杰尔·劳里等五名曾就职于知名游戏发行公司Gathering of Developers和Gamecock Media Group的高管，于2009年6月创立，以对开发者友好的合作模式著称。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
DRCT vs PLX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.4M | $9.1M |
| 净利润 | $-11.7M | $-5.5M |
| 毛利率 | 26.8% | 49.4% |
| 营业利润率 | -53.4% | -51.1% |
| 净利率 | -138.7% | -60.3% |
| 营收同比 | -7.4% | -49.9% |
| 净利润同比 | -434.7% | -184.8% |
| 每股收益（稀释后） | $-74.97 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $8.4M | $9.1M | ||
| Q3 25 | $8.0M | $17.9M | ||
| Q2 25 | $10.1M | $15.7M | ||
| Q1 25 | $8.2M | $10.1M | ||
| Q4 24 | $9.1M | $18.2M | ||
| Q3 24 | $9.1M | $18.0M | ||
| Q2 24 | $21.9M | $13.5M | ||
| Q1 24 | $22.3M | — |
| Q4 25 | $-11.7M | $-5.5M | ||
| Q3 25 | $-2.7M | $2.4M | ||
| Q2 25 | $-2.2M | $164.0K | ||
| Q1 25 | $-2.4M | $-3.6M | ||
| Q4 24 | $-2.2M | $6.5M | ||
| Q3 24 | $-2.7M | $3.2M | ||
| Q2 24 | $-590.0K | $-2.2M | ||
| Q1 24 | $-775.0K | — |
| Q4 25 | 26.8% | 49.4% | ||
| Q3 25 | 27.7% | 53.4% | ||
| Q2 25 | 35.1% | 62.5% | ||
| Q1 25 | 29.3% | 19.1% | ||
| Q4 24 | 32.5% | 78.7% | ||
| Q3 24 | 38.7% | 53.4% | ||
| Q2 24 | 27.1% | 29.8% | ||
| Q1 24 | 22.4% | — |
| Q4 25 | -53.4% | -51.1% | ||
| Q3 25 | -49.0% | 11.9% | ||
| Q2 25 | -23.9% | 7.5% | ||
| Q1 25 | -48.1% | -41.0% | ||
| Q4 24 | -51.8% | 39.6% | ||
| Q3 24 | -40.3% | 22.2% | ||
| Q2 24 | -9.4% | -18.0% | ||
| Q1 24 | -12.6% | — |
| Q4 25 | -138.7% | -60.3% | ||
| Q3 25 | -33.6% | 13.2% | ||
| Q2 25 | -22.2% | 1.0% | ||
| Q1 25 | -28.9% | -35.8% | ||
| Q4 24 | -24.0% | 35.6% | ||
| Q3 24 | -29.6% | 18.0% | ||
| Q2 24 | -2.7% | -16.4% | ||
| Q1 24 | -3.5% | — |
| Q4 25 | $-74.97 | $-0.06 | ||
| Q3 25 | $-0.24 | $0.03 | ||
| Q2 25 | $-0.23 | $0.00 | ||
| Q1 25 | $-0.35 | $-0.05 | ||
| Q4 24 | $-90.17 | $0.10 | ||
| Q3 24 | $-0.71 | $0.03 | ||
| Q2 24 | $-0.16 | $-0.03 | ||
| Q1 24 | $-0.22 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $728.0K | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-7.0M | $48.2M |
| 总资产 | $20.2M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $728.0K | $14.7M | ||
| Q3 25 | $871.0K | $13.6M | ||
| Q2 25 | $1.6M | $17.9M | ||
| Q1 25 | $1.8M | $19.5M | ||
| Q4 24 | $1.4M | $19.8M | ||
| Q3 24 | $4.1M | $27.4M | ||
| Q2 24 | $1.1M | $23.4M | ||
| Q1 24 | $3.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $33.5M | — | ||
| Q1 25 | $32.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $150.0K | — | ||
| Q2 24 | $34.8M | — | ||
| Q1 24 | $32.4M | — |
| Q4 25 | $-7.0M | $48.2M | ||
| Q3 25 | $-6.7M | $52.9M | ||
| Q2 25 | $-24.6M | $49.9M | ||
| Q1 25 | $-23.3M | $45.2M | ||
| Q4 24 | $-19.7M | $43.2M | ||
| Q3 24 | $-16.7M | $32.4M | ||
| Q2 24 | $-10.5M | $28.6M | ||
| Q1 24 | $-7.5M | — |
| Q4 25 | $20.2M | $82.3M | ||
| Q3 25 | $22.5M | $82.3M | ||
| Q2 25 | $23.3M | $78.5M | ||
| Q1 25 | $23.8M | $73.9M | ||
| Q4 24 | $26.0M | $73.4M | ||
| Q3 24 | $31.3M | $61.6M | ||
| Q2 24 | $48.5M | $91.5M | ||
| Q1 24 | $52.8M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-1.9M | $2.0M | ||
| Q3 25 | $-1.6M | $-3.7M | ||
| Q2 25 | $-2.7M | $-5.2M | ||
| Q1 25 | $-2.7M | $-5.1M | ||
| Q4 24 | $-1.6M | $4.0M | ||
| Q3 24 | $3.0M | $4.1M | ||
| Q2 24 | $-4.4M | $-3.6M | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DRCT
| Buy Side Advertising | $8.2M | 98% |
| Other | $183.0K | 2% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
